This paper describes a preliminary investigation into the bronchodilator action of khellin in patients with clinical bronchospasm.
THE BRONCHODILATOR ACTION OF KHELLIN lungs can be filled and emptied of air. Variations in the bronchial lumen will thus be reflected in corresponding variatibns in the maximum ventilatory capacity which the patient can achieve. Therefore, in assessing a supposed bronchodilator, it seems reasonable to take the maximum ventilatory capacity as an index of the degree of bronchoconstriction existing before, during, and after treatment with the drug under trial.
The maximum breathing capacity test (M.B.C.) as introduced by Hermannsen in 1933, and more recently described by other workers (Comroe, 1950) , is the accepted method in current use for assessing the maximum ventilatory capacity. In this test the volume of air shifted over a short time interval is measured while the patient is breathing as deeply and as quickly as possible. The result is expressed in litres per minute. However, the M.B.C. test has the disadvantage of being fatiguing and time-consuming to both patient and observer, and further, there appears to be a considerable "learning " effect, which is a disadvantage in outpatient work.
Kennedy (1949) suggested that it might be possible to predict the patient's maximum breathing capacity from the analysis of single expiratory vital capacity tracings recorded on a fast-moving kymograph, and Fig. 1 shows examples of tracings in six subjects. From the examination of many hundreds CLIMICAL-VITAL CAPACITY of such tracings it was found that they could, in general, be divided into three fractions as shown in Fig. 2 . In the first fraction of the tracing the flow M t Lm \V\ rate is maximum and relatively uniform. The second fraction V' I is generally curved, and is less cap",U steep than the first, but the I third or terminal fraction is \ undulatory. It was shown that 1C c Ot "A the slope of the first steep frac-\ Wluu tion of the curve appeared to determine the patient's maximum breathing capacity.
During the past two years various methods of recording I'" u and analysing these tracings I have been studied to obtain a I I valid measure of ventilatory capacity (Kennedy, 1951) . 4 However, all that need be said here is that half the mean-| (5i c5.)-> expiratory flow *rate (E.F.R.) expressed in litres/minute, FIG. 2.-Diagrammatic sketch of a vital capacity tracing.
expre iThe section marked I is that used in estimating the measured over the first 0.75 expiratory flow rate. subjects. M.B.C. was estimated by the method de cribed by Gilson and Hugh-Jones (1949) second of an expiratory vital capacity tracing (Fig. 3 with a standard error of +5 %. We have, therefore, adopted this method as our principal objective measure for assessing the bronchodilator effect of khellin. We have also recorded the vital capacity and, in many instances, the observed maximum breathing capacity, and some of these data will be presented.
It is, of course, known that the expiratory flow rate is determined by a number of factors in addition to the lumen of the bronchial tree, as, for example, by the tone of the expiratory musculature, the rigidity of the chest wall, and the power of elastic recoil of the lung. We, therefore, felt that we should attempt to assess, when investigating a patient, the degree of reversible bronchoconstriction present as opposed to other irreversible changes affecting the air-flow rate. Theoretically, it should be possible to assess the degree of reversible bronchoconstriction in a given patient by measuring the ventilatory capacity before and again after the administration of a proved bronchodilator. This has been attempted by employing a modification of Rossier and Mean's adrenaline test (1936) . In this modification the expiratory air-flow rate is measured before and after a 15-minute inhalation of a 1/1,000 solution of adrenaline.* Fig. 4 is an example of changes in the expiratory air-flow rate following the inhalation of adrenaline. 
PROCEDURE
In general, the procedure adopted in the study of each patient falls under three main headings: (1) a pre-trial assessment to obtain " base-line " data ; (2) the effect of a single intramuscular injection of khellin on the first day of trial; (3) the subsequent progress on alternating courses of oral khellin and placebo tablets. (1) THE PRE-TRIAL ASSESSMENT.-The expiratory flow rate, vital capacity, and maximum breathing capacity of patients who had been clinically selected for trial were measured before and after an adrenaline inhalation on two or more different days before treatment with khellin. The purpose of the adrenaline test here was both to determine whether the patient had reversible bronchoconstriction and also to provide a possible yardstick against which we could measure the effect of khellin. Further, from the study of the E.F.R. values on different days before giving adrenaline, we hoped to obtain a measure of the day-to-day variability of the degree of bronchoconstriction and a " base-line " value.
(2) EFFECT OF A SINGLE INTRAMUSCULAR INJECTION OF KHELLIN.-Each patient was clinically and objectively assessed before and half an hour after an injection of sterile water. The patient was then given an intramuscular injection of khellin and the assessment was repeated a quarter of an hour later and thereafter at intervals of half to three-quarters of an hour over a three-to four-hour period. At the end of the period of observation a final assessment was carried out after a 15-minute inhalation of adrenaline. In the clinical assessment at each of these times, changes of colour, dyspnoea, wheezing, and audible rhonchi were noted. For the objective assessment, the E.F.R., vital capacity (V.C.), and blood pressure were measured on each occasion. The assessments before and after the injection of water were made to provide further data for the " base-line " and to exclude the possibility of any response to the injection of khellin being psychological in origin.
(3) SUBSEQUENT PROGRESS ON ORAL KHELLIN AND PLACEBO.-Twenty-four to 48 hours after the intramuscular injection of khellin, the patient was again assessed clinically and objectively. He was then given oral khellin for approximately a week and then changed, without his knowledge, to placebo tablets for a further week. Another course of oral khellin was then given, usually with an increased dose. Throughout this period the patients were asked to attend three times each week for objective assessment, when the E.F.R. and V.C. were measured before and after an adrenaline inhalation. The observer making these measurements did not know whether the patients were receiving khellin or placebo tablets. This is the broad outline of the trial as originally planned. Unfortunately, however, for yarious reasons some patients were unable to adhere strictly to this routine. More recently blood levels of the drug have been estimated following both intramuscular and oral medication.
CLINICAL MATERIAL
In most cases of asthma bronchoconstriction tends to be an ephemeral and elusive manifestation with wide and unpredictable fluctuations, both throughout the 24 hours and from day to day. Objective measurements in such cases, therefore, made at arbitrary times and on arbitrary dates are likely to show considerable spontaneous variations, independent of therapy. Since these would make it difficult to distinguish the effects of treatment and control periods from the natural history of the disease, at least without prolonged observation, we decided to select for investigation cases showing a persistent and relatively stable bronchoconstriction with, as far as possible, infrequent severe attacks. Thus the main criterion deter-mining the selection of cases was that they should constantly present those clinical features generally regarded as evidence of bronchospasm or mucosal oedema, including persistent " wheezy " breathing, inspiratory and expiratory rhonchi, and a variable degree of dyspnoea. All cases also showed a positive response to the adrenaline test which was taken as confirmatory evidence of the presence of reversible bronchoconstriction.
Twelve patients were chosen for the initial trial and comprise a somewhat heterogeneous series taken partly from a medical out-patient clinic and partly from patients attending a silicosis unit. Broadly speaking, they fall into two groups: the first, chronic asthmatics showing evidence of persistent bronchoconstriction between their more florid attacks; the second, mainly middle-aged patients with chronic bronchitis and clinical emphysema, with or without pneumoconiosis, in whom a reversible bronchoconstriction was regarded as a significant contributory factor in their disability.
ADMINISTRATION OF KHELLIN Throughout this investigation khellin has been administered either by the intramuscular or oral routes. It is relatively insoluble in water, but is soluble in a 50% solution of sodium salicylate. A 5% solution of khellin in this vehicle has been used for the intramuscular injections. More recently propylene glycol has been used as the solvent. Oral khellin has been given as 25 or 50 mg. tablets with lactose. The placebo tablets consisted of lactose only. The intramuscular dose has varied between 150 and 400 mg. The oral dose has largely been determined by the patient's tolerance and has varied from 50 to 400 mg. daily.
RESULTS
The changes in the E.F.R. and V.C. findings have been charted graphically for all 12 patients. From the graphs, five out of the 12 appeared to be improved after the intramuscular or oral administration of khellin, and have been re-numbered 1 to 5, and the changes in E.F.R. in relation to their treatment shown in Figs. 5 to 9, and summarized in Table I Unfortunately, this laa had no pre-trial assessment, but he was observed on eight different days over a 42-day period while receiving the placebo tablets; a study of his E.F.R. on these days gave us a good idea of the day-to-day variability of the dqgree of bronchoconstriction present (Fig. 7) . On the first day of the trial the patient was cyanosed and exhibited expiratory rhonchi over both lungs. Before and after the injection of water his E.F.R. was 35 and 32 litres per minute respectively. After an intramuscular injection of khellin, his clinical condition and E.F.R. gradually improved, until two and a half hours after the injection the cyanosis and rhonchi had disappeared and the E.F.R. was 55 litres per minute.
He was then given oral khellin, 50 mg. twice daily. Five days after his injection and after receiving oral khellin for three days, his E.F.R had risen to 63 litres per minute. This is the highest reading obtained over more than 130 days' observation. After taking khellin for one week, he received placebo tablets for one week, when he became so much worse that he required frequent injections of adrenaline. One record of his E.F.R. obtained at this time was only 25 litres per minute, and this was made one hour after an injection of 5 minims (0.3 ml.) of adrenaline, 1 : 1000. Oral khellin was then given again and his asthma attacks ceased. He was discharged from hospital and continued to take khellin by mouth for 43 days, during which time he remained free from attacks, and his parents stated that he was better than they had known him since infancy. During a further 42 days on placebo tablets his asthma attacks returned, though the severity was stated to be less, and they again disapp2ared when khellin was restarted.
Despite the apparent clinical improvement on khellin, there is no striking difference between his measured E.F.R. values during these recent treatment and control periods. He deteriorated when placebo tablets were substituted, and improved again when khellin was given for a second time. Side effects proved troublesome, and at first he could tarely tolerate more than 150 mg. of khellin daily by mouth. Later he received enteric-protected tablets and it became possible to increase his dose to 300 mg. daily. On this dosage the peak E.F.R. increased to 67 litres per minute before adrenaline, rising to 108 litres per minute after an adrenaline inhalation. The variations in the E.F.R. during treatment and control periods before and after adrenaline can be seen in Fig.   8 The E.F.R. gradually increased after the intramuscular injection of 300 mg. khellin to 61 litres per minute in three hours. At the end of this period,-the rhonchi were slightly diminished, but there was no other clinical change. During his first period of oral khellin, 50 mg. thrice daily, the E.F.R. was maintained at the improved level of between 61-and 64 litres per minute. Clinically, this improvement was overshadowed by severe side effects. He noticed, however, that he could walk up the three flights of stairs to his flat without stopping, which normally he was unable to do, and his wife stated that his customary nocturnal wheezing had ceased. No rhonchi were audible. During the placebo period, the E.F.R. fell to his base-line level, and nocturnal wheezing returned. During his second period of khellin therapy the E.F.R. again improved, but side effects were so severe that treatment could not be continued (Fig. 9) .
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_ ; Ub 40~~~~F IG. 9 In Table I a mean base-line level has been estimated for each patient before (a) and after (/8) the inhalation of adrenaline. The percentage change from these base-line values has been estimated, one hour, four hours, and 24 hours after a single intramuscular injection of khellin and also during the periods of administration of oral khellin and of placebo tablets.
All patients but one showed a greater increase in E.F.R. during their first period on oral khellin than during the second. The one exception is No. 4, who received a larger dose of khellin during the second period. This suggests that the intramuscular injection of khellin enhanced the effect of the first period of oral khellin.
The vital capacity data have been treated in the same way as the E.F.R. data and are presented in Table II. In Table III PATIENTS NOT, IMPROVED BY KHELLIN The remaining seven cases showed no conclusive evidence of a response to khellin. They included two chronic asthmatics, two pneumoconiotics with a positive response to the adrenaline test, and three cases of chronic bronchitis with severe emphysema.
The two chronic asthmatics appeared to respond clinically to the drug, but unfortunately our objective data are incomplete. Of the remaining five patients, none showed a response to a single intramuscular injection of khellin. In three, side effects were so severe that an adequate trial with oral khellin proved impossible. One of the other two patients was too ill for us to assess the effects of the drug, and the remaining patient showed no response, despite an adequate trial.
FURTHER STUDIES
Further studies have been carried out to determine when the peak effect of a single intramuscular injection of khellin is reached and how long the effect lasts. The response to a single large dose of khellin given by mouth, and the varying response with varying doses, has also been investigated. These later studies have been related to khellin blood-level findings. The data on three patients (two have already been described) are presented to illustrate these points.
Patient No. 2.-This man maintained his improvement for three months on oral khellin, when placebo tablets were substituted, and he quickly became so much worse that he was re-admitted to hospital. He was again orthopnoeic, cyanosed, and wheezy, with expiratory and inspiratory rhonchi. On April 13, the E.F.R. was 25 litres per minute before adrenaline and 34 litres per minute after. After three days' rest in hospital he improved, and the E.F.R. rose to 60 litres per minute before adrenaline and 70 litres per minute after. Next morning, on April 17, he was given a single intramuscular injection of 400 mg. khellin, and the V.C. and E.F.R. before and after adrenaline were recorded twice daily for three days. The results are shown in Fig. 10 given over a five-day period, is considerably less than the previous peak obtained after 3 g. of khellin over 12 days, and provides evidence for a cumulative effect of the drug.
This patient suffered no side effects from oral khellin, and took a dose of 400 mg. daily during the final period when the E.F.R. rose to a peak of 124 litres per minute. When this point was reached, no further improvement occurred after an adrenaline inhalation.
Patient No. 4.-Further studies are summarized in Fig. 11 . After each of two single intramuscular injections of 300 mg. on April 2 and 9, the peak response occurred 24 hours after the injection. After the injection on April 2, the response was maintained for roughly 72 hours; after the injection on April 9, improvement lasted less than 48 hours.
On April 16, when the E.F.R. was 26 litres per minute, he was given a single intramuscular injection of 400 mg. khellin. Twenty-four hours later the E.F.R. had risen to 35 litres per minute, and another injection of 400 mg. was given. On April 18 the E.F.R. had risen to 41 litres per minute, and three days later to a peak of 65 litres per minute, rising to 102 litres per minute after adrenaline. On the next day the E.F.R. had begun to fall and then gradually waned. These findings strongly suggest that intramuscular injections given consecutively within a 24-hour period produce a cumulative effect.
On Patient No. 36.-This patient, a chronic asthmatic, aged 50, is included, since he shows a similar picture to the previous patient after a single intramuscular injection of khellin. He achieved a peak response 25+ hours after an injection of 400 mg. khellin (Fig. 12 ). Thirty and a half hours after the injection the E.F.R. was good but lower, but by 73 hours it had returned to its original level. On all subjects the effect appears simply additive, adrenaline having the same effect on the patient whether or not he had had khellin, and vice versa. The data give no evidence of a reduced or enhanced effect from combining the drugs.
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It should be noted, however, that Patient 2 at the end of six aays' treatment with 400 mg. khellin daily by mouth attained a peak of 124 litres per minute, which is almost a normal reading for a man of his age and build, and that after this an inhalation of adrenaline produced no further improvement. 
THE BRONCHODILATOR ACTION OF KHELLIN SIDE EFFECTS
At present side effects, particularly nausea, are frequent and troublesome after the therapeutic use of khellin. Armbrust and Levine (1950) reported " uncomfortable" side effects, anorexia, nausea, and dizziness, in 60% of 53 cases of angina pectoris treated with oral khellin. Rosenman and others (1950) give a similar incidence for 30 cases, 53% experiencing significant side effects. In 40 cases treated with oral khellin, we found that by far the most important side effects are nausea and anorexia with occasional vomiting. A few patients have complained of somnolence, dizziness, and irritability while taking the drug, but these have been relatively trivial in comparison with nausea and would in no case have interfered with continued administration. We have not encountered any skin eruptions during treatment with the drug.
The incidence and severity of nausea in our patients is shown in Table IV .
Some degree of nausea occurred in 26 (65%) of the cases. In four cases (10%) this was relatively mild and did not interfere with treatment. In nine (22.5%) it was sufficiently severe to necessitate suboptimal dosage and in 13 (32.5%) it was prohibitive and led to the abandonment of oral therapy. When severe the nausea is more or less continuous and is particularly incapacitating. It may be associated with almost complete anorexia and vomiting occurs once or twice in the day. The patient rapidly becomes dejected, miserable, and apathetic, often despite dramatic amelioration of his dyspnoea. In less severe cases the nausea is intermittent and is often controllable by simple reduction of dosage. In a few cases, the nausea appears almost from the very first dose of the drug. More usually, however, it is delayed until the third or fourth day of treatment or even later. If nausea is severe, it tends to persist for 24 to 48 hours after the drug is discontinued. Side effects are always more obtrusive in ambulant patients than in those resting quietly in bed. This possibly explains the apparently low incidence in cases of chronic cor pulmonale.
The delay in the appearance of symptoms and their tendency to persist after the drug is stopped suggest that the effect is cumulative and might be central in origin. On the other hand, side effects after intramuscular injections are much less marked. Four patients, who were unable to tolerate the drug orally, were given 300 mg. daily intramuscularly for 10 days. All began to experience nausea on about the fourth day of treatment and two vomited. In one case, injections had to be discontinued, but in the other three the nausea quickly wore off and by the end of a week the only untoward symptom was mild anorexia in two of the cases.
These findings suggest that the nausea is largely due to a local irritant effect on the gastric mucosa, but a central effect cannot be entirely excluded. It was hoped that the local effect might be overcome by using a tablet in which the individual khellin granules were coated with stearic acid so that disintegration of the tablet with liberation of the drug would be-delayed until the small intestine was reached. Use of these " enteric-protected " tablets has certainly reduced the incidence and severity of nausea and has enabled some, patients to tolerate an effective dose of the drug which was previously impossible. However, a further reduction in the incidence of side effects will be essential before administration of the drug orally will be possible in every case.
No significant changes have been noted in the blood pressure, haemoglobin levels, or red or white cell counts after intramuscular or oral khellin administration.
BLOOD LEVELS OF KHELLIN The blood level of khellin has been estimated in a number of cases after both intramuscular and orai medication. The method of estimation employed is accurate to + 0.5 Ag. per ml. of blood. We hoped that it might be possible to relate the level of the drug in the blood to its physiological effect and thus obtain a simple guide to the best dosage. Our preliminary findings indicate that this is unlikely to prove feasible. The drug is rapidly absorbed by the intramuscular route, reaching a peak blood level in half to one hour, but then rapidly falling to undetectable levels. For example, in patient No. 2, after 400 mg. intramuscularly, the blood levels half, one, two, and four hours after injection were 2.5 Ag, 2.5 jug, less than 0.9 ug. per ml., and zero respectively. A similar type of curve, though more. delayed and variable, follows oral administration. Values are by no means constant from patient to patient. In patients receiving continuous medication, early morning levels have been estimated on a number of occasions before any drug has been given that day. No khellin has been detected in any of these samples.
DISCUSSION
Measurement of the expiratory flow rate in the manner described has proved a convenient method for assessing changes in the ventilatory capacity and thus variations in the bronchial lumen. Variations in the expiratory flow rate and vital capacity in individuals showed a similar trend when expressed as a percentage change (Table III) and this point merits further investigation. However, it has been shown (Gilson and Hugh-Jones, 1949 ) that the vital capacity is a poor index of ventilatory function and that the maximum breathing capacity bears a much closer relationship to the clinical grade of dyspnoea. The measurement of the expiratory flow rate combines the advantages of the maximum breathing capacity test with the simplicity of the vital capacity method.
In the early stages of this work a number of difficulties seriously interfered with our original plan of investigation. In the first place, as already indicated, the high incidence of side effects prevented an adequate trial of oral khellin in several cases. A second difficulty was the incidence of intercurrent respiratory infections, particularly among the cases with chronic bronchitis, which tended to obscure the picture. Three of the 12 patients died during the influenzal epidemic in the early months of 1951. Because of these difficulties, our data are not complete, and we cannot discuss the 12 cases as a whole. Five patients, however, showed improved expiratory flow rates after khellin and our objective data on these patients are sufficiently complete to justify some provisional conclusions.
The bronchodilator effect of a single intramuscular injection of khellin is delaved for at least an hour, is gradual in onset, and the peak effect is not attained until after six to 24 hours. On the other hand, once an effect appears it may be sustained over 24 hours or even longer. This observation is at variance with the findings of Kenawy and others (1950) and of Rosenman and others (1950) who state that a response may be seen within five to 10 minutes, with a peak in half to one hour. We have not observed a similar rapid response in any of our cases. It seems unlikely that this delayed physiological effect can be explained by a delay in absorption from the injection site, for we have found that the blood level after intramuscular injection reaches a peak in half to one hour, and by the time the bronchodilator effect is significant no khellin can be detected in blood samples.
In addition to the sustained effect of single doses of khellin, repeated daily dosage by the intramuscular or oral route appears to have a cumulative bronchodilator action. This cumulative effect is well exemplified from the further study of cases 2 and 4 (Figs. 10 and 11).
As a corollary to its sustained bronchodilator action, khellin appears to be especially effective in reducing the frequency and severity of acute attacks in the chronic asthmatic. This effect was noted in patient number 3 and has been observed in a number of other cases not included in the present series.
We have insufficient data to determine the best dosage, by intramuscular or oral routes: 200-400 mg. as a single intramuscular injection appears to be well tolerated and to be effective in cases which respond. The oral dosage is largely determined by the patient's tolerance. However, from the data presented and from other material available, it appears that not less than 150 mg. daily is the minimum effective dos2 for the average adult, and 300-400 mg. daily is desirable. We have evidence that w:th continued administration, some degree of resistance to the drug develops, necessitating higher dosage to obtain the same effect.
The quantitative response to khellin varied in the different clinical typ2s. Patients with chronic asthma showed a much greater improvement in E.F.R. after khellin (from 64% to 239%) than those with chronic bronchitis and emphysema (from 18% to 26%). All 12 patients in the series showed improvement in E.F.R. after inhalation of adrenaline. This adrenaline effect varied between 20% and 150% and.
like the khellin effect, was greater in patients with chronic asthma than in those with chronic bronchitis and emphysema. Originally it had been hoped that the adrenaline test would serve the dual purpose cf indicating the degree of reversible broncho-constriction and of providing a measure against which the effect of khellin could be judged. Our findings suggest that a modification in the interpretation of this test is necessary. When adrenaline and khellin are given together, the effect of the two drugs appears to be additive, and the response to adrenaline remains substantially the same, even at the peak of a khellin effect. This observation strongly suggests that the action of the two drugs is different. From animal experiments with khellin (Samaan, 1932; Anrep, Barsoum, and Kenawy, 1949) it seems very probable that its pharmacological action is on the smooth muscle in the bronchial wall. On the other hand, adrenaline inhalations, in view of their mode of administration, may act mainly on the mucous membrane lining the bronchi, although the recent work of Sheldon and Otis (1951) suggests that the subcutaneous injection of adrenaline may produce pulmonary vascular constriction rather than bronchiolar dilation in certain cases. The hypothesis of a primary mucosal effect of inhaled adrenaline leads to some interesting speculations about the pathogenesis of reversible bronchoconstriction in the different clinical types of case. In the chronic bronchitic, the adrenaline response and the khellin response are roughly equal, suggesting that the mucosa and the smooth muscle are equally affected, whereas in the chronic asthmatic the khellin response is appreciably greater than the adrenarine response, indicating that in these' cases spasm of the bronchial muscle is the main cause of the reversible bronchoconstriction. These findings emphasize that reversible bronchoconstriction may be due to multiple factors, and that its most efficient relief requires a combination of drugs, each at optimal dosage. This preliminary report has been mainly concerned with the objective demonstration of the bronchodilator effect of khellin in a number of selected cases. Its use as a practical therapeutic agent still remains to be determined. However, its property of producing a sustained increase in the ventilatory capacity may be of the greatest value in the management of certain chronic asthmatics and chronic bronchitics in whom a true bronchospasm is a significant contributory factor. The main problem still requiring solution is the high incidence of side effects when the drug is given orally, for at present in many cases the only feasible method of maintaining adequate dosage is by daily intramuscular injection which presents obvious difficulties in practice.
We consider that the results are sufficiently encouraging to warrant further work on the action and clinical use of khellin as a bronchodilator. SUMMARY Some of the difficulties in the investigation of a bronchodilator drug are discussed.
Variations in the bronchial lumen are accompanied by corresponding variations in ventilatory capacity. The ventilatory capacity has been assessed by measuring half the mean expiratory flow rate (E.F.R.) over the first three-quarter second period of six consecutive expiratory vital capacity tracings using a simple spirometer and a fast-moving synchronous kymograph. This measure (E.F.R.) correlates well with the observed maximum breathing capacity (r= + 0.927) and is a simple and convenient method in clinical work.
